Consistently, the intestinal microbiota could increase the effectiveness and/or the sensitivity of the treatment with anti PD-1 against HCC [69, 70], which suggests that the modulation of gut microbiota can manage to increase the activity of HCC treatments. Here, PDCD1 is linked to hepatocellular carcinoma.